CLICK HERE to access the June 2021 review of novel treatments in haemophilia and other bleeding disorders by the European Haemophilia Consortium.
The CHS is pleased to share its brand new five-year strategic framework following an extensive strategic planning exercise held in 2020. The strategy is expressed...
On May 25, 2021, Canadian Blood Services (CBS) released its recommendation on emicizumab (Hemlibra) to the provincial/territorial Ministers of Health. CBS recommends that emicizumab be listed...
Updated charts for products in the pipeline have been uploaded on the CHS website. The CHS publishes four charts, one each for clotting factor concentrates,...
Montreal, February 4, 2021 – The hemophilia community is awaiting decisions by Canadian health authorities on access to Hemlibra for people with hemophilia A without...
